We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insulet (PODD) Down 8.2% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
A month has gone by since the last earnings report for Insulet (PODD - Free Report) . Shares have lost about 8.2% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Insulet due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Insulet Corporation before we dive into how investors and analysts have reacted as of late.
Insulet Tops Q4 Earnings & Revenue Estimates
Insulet Corporation reported fourth-quarter 2025 adjusted earnings per share of $1.55, up 34.8% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 4.87%.
GAAP earnings per share came in at $1.44, up 3.6% from the year-ago quarter’s figure.
Full-year 2025 earnings per share of $4.97 increased 53.4% from the prior-year level. The figure topped the Zacks Consensus Estimate by 1.2%.
PODD’s Revenues
Revenues totaled $783.8 million, which beat the Zacks Consensus Estimate by 2.15%. The top line jumped 31.2% year over year and 29% at constant exchange rate or CER, which exceeded the company’s high end of the guidance range of 25%-28%.
Insulet reported full-year 2025 revenues of $2.71 billion, which increased 30.7% from the prior-year level. The figure surpassed the Zacks Consensus Estimate by 0.7%.
PODD’s Q4 Segmental Revenues
Insulet’s total Omnipod revenues of $781.8 million reflected an increase of 33.5% year over year and 31.3% at CER.
International Omnipod revenues of $214 million rose 50.7% (up 41.7% at CER). U.S. Omnipod revenues grew 28% year over year to $567.8 million.
The Drug Delivery business’ revenues totaled $2 million, down 83.4% year over year.
PODD’s Q4 Margin Performance
The gross profit in the reported quarter was $568.6 million, up 31.9% from the prior-year quarter’s figure. The gross margin of 72.5% expanded 32 basis points (bps) year over year.
Selling, general & administrative expenses rose 27% year over year to $331.4 million.
Research and development expenses jumped 50% year over year to $90.9 million.
The operating profit in the quarter totaled $146.3 million, up 33.7% from the year-ago reported actuals. The operating margin of 18.7% expanded 36 bps year over year.
Insulet’s Cash Position
Insulet exited the fourth quarter of 2025 with cash and cash equivalents of $716.1 million compared with $953.4 million at the end of 2024.
Cumulative net cash provided by operating activities at the end of the fourth quarter was $569.3 million compared with $430.2 million in the year-ago period.
PODD’s 2026 Outlook
Insulet provided guidance for full-year 2026. Total revenues are projected to grow 20%-22% at CER. Within this, Total Omnipod revenue growth is expected in the range of 21%-23%, while Drug Delivery revenues are expected to fall around 50% at CER. The Zacks Consensus Estimate for the company’s 2025 revenues currently stands at $2.69 billion.
For the first quarter, Insulet projects revenue growth of 25%-27%. Total Omnipod revenues are anticipated to rise 28%-30%. Drug Delivery revenues are expected to decline roughly 80%. The consensus mark for the company’s first-quarter revenues currently stands at $767.3 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
At this time, Insulet has a strong Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock has a grade of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Insulet has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Insulet is part of the Zacks Medical - Products industry. Over the past month, Phibro Animal Health (PAHC - Free Report) , a stock from the same industry, has gained 1%. The company reported its results for the quarter ended December 2025 more than a month ago.
Phibro reported revenues of $373.9 million in the last reported quarter, representing a year-over-year change of +20.9%. EPS of $0.87 for the same period compares with $0.54 a year ago.
Phibro is expected to post earnings of $0.72 per share for the current quarter, representing a year-over-year change of +14.3%. Over the last 30 days, the Zacks Consensus Estimate has changed +1.1%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #1 (Strong Buy) for Phibro. Also, the stock has a VGM Score of D.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Insulet (PODD) Down 8.2% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Insulet (PODD - Free Report) . Shares have lost about 8.2% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Insulet due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Insulet Corporation before we dive into how investors and analysts have reacted as of late.
Insulet Tops Q4 Earnings & Revenue Estimates
Insulet Corporation reported fourth-quarter 2025 adjusted earnings per share of $1.55, up 34.8% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 4.87%.
GAAP earnings per share came in at $1.44, up 3.6% from the year-ago quarter’s figure.
Full-year 2025 earnings per share of $4.97 increased 53.4% from the prior-year level. The figure topped the Zacks Consensus Estimate by 1.2%.
PODD’s Revenues
Revenues totaled $783.8 million, which beat the Zacks Consensus Estimate by 2.15%. The top line jumped 31.2% year over year and 29% at constant exchange rate or CER, which exceeded the company’s high end of the guidance range of 25%-28%.
Insulet reported full-year 2025 revenues of $2.71 billion, which increased 30.7% from the prior-year level. The figure surpassed the Zacks Consensus Estimate by 0.7%.
PODD’s Q4 Segmental Revenues
Insulet’s total Omnipod revenues of $781.8 million reflected an increase of 33.5% year over year and 31.3% at CER.
International Omnipod revenues of $214 million rose 50.7% (up 41.7% at CER). U.S. Omnipod revenues grew 28% year over year to $567.8 million.
The Drug Delivery business’ revenues totaled $2 million, down 83.4% year over year.
PODD’s Q4 Margin Performance
The gross profit in the reported quarter was $568.6 million, up 31.9% from the prior-year quarter’s figure. The gross margin of 72.5% expanded 32 basis points (bps) year over year.
Selling, general & administrative expenses rose 27% year over year to $331.4 million.
Research and development expenses jumped 50% year over year to $90.9 million.
The operating profit in the quarter totaled $146.3 million, up 33.7% from the year-ago reported actuals. The operating margin of 18.7% expanded 36 bps year over year.
Insulet’s Cash Position
Insulet exited the fourth quarter of 2025 with cash and cash equivalents of $716.1 million compared with $953.4 million at the end of 2024.
Cumulative net cash provided by operating activities at the end of the fourth quarter was $569.3 million compared with $430.2 million in the year-ago period.
PODD’s 2026 Outlook
Insulet provided guidance for full-year 2026. Total revenues are projected to grow 20%-22% at CER. Within this, Total Omnipod revenue growth is expected in the range of 21%-23%, while Drug Delivery revenues are expected to fall around 50% at CER. The Zacks Consensus Estimate for the company’s 2025 revenues currently stands at $2.69 billion.
For the first quarter, Insulet projects revenue growth of 25%-27%. Total Omnipod revenues are anticipated to rise 28%-30%. Drug Delivery revenues are expected to decline roughly 80%. The consensus mark for the company’s first-quarter revenues currently stands at $767.3 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
At this time, Insulet has a strong Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock has a grade of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Insulet has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Insulet is part of the Zacks Medical - Products industry. Over the past month, Phibro Animal Health (PAHC - Free Report) , a stock from the same industry, has gained 1%. The company reported its results for the quarter ended December 2025 more than a month ago.
Phibro reported revenues of $373.9 million in the last reported quarter, representing a year-over-year change of +20.9%. EPS of $0.87 for the same period compares with $0.54 a year ago.
Phibro is expected to post earnings of $0.72 per share for the current quarter, representing a year-over-year change of +14.3%. Over the last 30 days, the Zacks Consensus Estimate has changed +1.1%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #1 (Strong Buy) for Phibro. Also, the stock has a VGM Score of D.